PMID- 35871036
OWN - NLM
STAT- MEDLINE
DCOM- 20221018
LR  - 20221018
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 121
IP  - 11
DP  - 2022 Nov
TI  - Roxadustat regulates iron metabolism in dialysis-dependent and 
      non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
PG  - 2288-2299
LID - S0929-6646(22)00247-9 [pii]
LID - 10.1016/j.jfma.2022.06.008 [doi]
AB  - BACKGROUND/PURPOSE: The effect of roxadustat on iron homeostasis in patients with 
      chronic kidney disease (CKD) is unclear. This study aimed to evaluate the 
      efficacy of roxadustat for the treatment of iron metabolism disorders in 
      dialysis-dependent (DD) and non-dialysis-dependent (NDD) CKD patients. METHODS: 
      We searched the PubMed, Embase, China National Knowledge Internet and Web of 
      Science databases for randomized controlled trials (RCTs). The primary outcomes 
      were changes in serum iron, total iron binding capacity (TIBC), transferrin 
      saturation (TSAT), ferritin, transferrin, and hepcidin. The secondary outcomes 
      included the changes in hemoglobin (Hb) and the incidences of adverse events 
      (AEs) and severe adverse events (SAEs). RESULTS: Twelve RCTs comprising 4976 
      participants were included. Compared to the control group, increases in the serum 
      iron (SMD = 0.21, 95% CI: 0.15 to 0.27, P < 0.00001), TIBC (SMD = 1.02, 95% CI: 
      0.82 to 1.22, P < 0.00001) and transferrin levels (WMD = 0.55, 95% CI: 0.41 to 
      0.69, P < 0.00001) were found in the roxadustat group. Compared to the control 
      group, decreases in the ferritin levels (WMD = -37.82, 95% CI: -59.89 to -15.74, 
      P = 0.0008) and hepcidin levels (WMD = -24.04, 95% CI: -36.28 to -11.79, 
      P = 0.0001) were observed in the roxadustat group. The meta-analysis showed that 
      roxadustat significantly increases Hb levels (WMD = 0.77, 95% CI: 0.42 to 1.12, 
      P < 0.0001). The incidences of AEs and SAEs in the roxadustat group was 
      significantly higher than that in the control group (RR = 1.03, 95% CI: 1.00 to 
      1.07, P = 0.04; RR = 1.08, 95% CI: 1.00 to 1.15, P = 0.04). CONCLUSION: Our 
      findings suggest that roxadustat could effectively improve iron metabolism in 
      patients with CKD.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Hou, Yan-Pei
AU  - Hou YP
AD  - Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of 
      Hainan Medical University, Haikou, China.
FAU - Wang, Chang
AU  - Wang C
AD  - Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of 
      Hainan Medical University, Haikou, China.
FAU - Mao, Xin-Yue
AU  - Mao XY
AD  - Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of 
      Hainan Medical University, Haikou, China.
FAU - Zhang, Man-Zhu
AU  - Zhang MZ
AD  - Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of 
      Hainan Medical University, Haikou, China.
FAU - Li, Bing
AU  - Li B
AD  - Department of Nephrology, Institute of Nephrology, 2nd Affiliated Hospital of 
      Hainan Medical University, Haikou, China. Electronic address: 
      icecreamlee@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220720
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (Hemoglobins)
RN  - 0 (Hepcidins)
RN  - 0 (Isoquinolines)
RN  - 0 (Transferrins)
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
RN  - TE7660XO1C (Glycine)
RN  - X3O30D9YMX (roxadustat)
SB  - IM
MH  - *Anemia/etiology
MH  - Ferritins
MH  - Glycine/analogs & derivatives
MH  - Hemoglobins/analysis
MH  - Hepcidins/metabolism
MH  - Humans
MH  - Iron
MH  - Isoquinolines
MH  - *Renal Insufficiency, Chronic/complications/therapy
MH  - Transferrins
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Iron metabolism
OT  - Meta-analysis
OT  - Roxadustat
COIS- Declaration of competing interest The authors report no conflict of interest 
      concerning the materials or methods used in this study or the findings specified 
      in this article.
EDAT- 2022/07/24 06:00
MHDA- 2022/10/19 06:00
CRDT- 2022/07/23 23:40
PHST- 2022/02/08 00:00 [received]
PHST- 2022/06/03 00:00 [revised]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
PHST- 2022/07/23 23:40 [entrez]
AID - S0929-6646(22)00247-9 [pii]
AID - 10.1016/j.jfma.2022.06.008 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2022 Nov;121(11):2288-2299. doi: 10.1016/j.jfma.2022.06.008. 
      Epub 2022 Jul 20.